Intravacc, a company involved in translational research and development of preventive and therapeutic vaccines, has been awarded $633,000 from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit organization for the development of a preventive vaccine against Neisseria gonorrhoeae (NG). The vaccine will be developed on Intravacc’s outer membrane vesicle (OMV) platform technology.

The CARB-X award supports the development of Intravacc’s meningococcal outer membrane vesicle (OMV) vaccine that carries several important gonococcal antigens aimed to prevent infections by Neisseria gonorrhoeae. Through the tailored gonococcal antigens on the surface of the meningococcal OMV, Intravacc anticipates a significant enhancement in the vaccine candidate’s efficacy against gonorrhea.

Erin Duffy, R&D chief of CARB-X said, “Resistant strains of Neisseria gonorrhoeae have evaded all but one existing antibiotic (ceftriaxone), vaccines are powerful tools in the prevention of bacterial infections. With an appropriate vaccination strategy, Intravacc’s vaccine project, if successful, could prevent the disease, and significantly curb the spread of resistant bacteria across the globe.”

Jan Groen, Intravacc’s CEO, said, “This CARB-X project allows us to combine our science and OMV expertise for the development of a vaccine against gonorrhea infections. We believe the outcome of this vaccine project could be an important contribution to the worldwide antimicrobial resistance epidemic.”
https://www.intravacc.nl